En
En
Fr
Fr
De
De
It
It
Es
Es
Cn
Cn

EXPERIENCIA CLÍNICA MUNDIAL DE 16 AÑOS DEL TRASPLANTE DE LAS CELULAS TRONCALES EMBRIONALES/FETALES HUMANAS

LA EXPERIENCIA MAS GRANDE DEL MUNDO EN EL TRASPLANTE DE LAS CELULAS TRONCALES EMBRIONALES PARA EL TRATAMIENTO DE DIFERENTES ENFERMEDADES Y ESTADOS

Pagina Principal
Informacion Sobre EmCell
Informacion Sobre la Terapia Celular
Nostre Esperienze
Lista de Enfermedades:
Enfermedades Oncologicas
Diabetes Sacarina
Enfermedades del Sistema Nervioso
Problemas de Envejecimiento
Estados de Inmunodeficencia
Tratamiento Endoscopico de las Enfermedades Hepaticas
Congresos y Conferencias
Video y otros materiales
FAQs
Correo

Embryonic Stem Cells in Duchenne Muscular Dystrophy



Registration Number: 121

Conference Abstract Book: page XXXIII

Embryonic Stem Cells in Duchenne Muscular Dystrophy

Olexander I. Smikodub

Cell Therapy Clinic of National Medical University of Ukraine

 and Embryonic Tissues Center EmCell

Solomenskaya Str. 17, POB 80, Kiev 03110, UKRAINE

Under observation were 78 DMD patients aged 3-18.  Diagnosis was confirmed by the genetic analysis.  Treatment was initiated at different stages, with variable stages of muscular atrophy and ambulatory ability (bedridden, wheelchair-bound, ambulant). Patients were administered mesenchymal, ectodermal, and endodermal SC obtained from germ layers of 4-8 weeks old cadaverous embryos’ systems and organs; amounts administered - 0,5-3 ml, cell count - 0,1-100x105/ml.  Our conclusions are based on 9 year’s observation experience of DMD patients. In the course of the first two months after the treatment, strength of different muscle groups increased by 100-700%, and was maintained at a high level for 8-15 months.  Besides, reported was also ROM increase, within the limits of the patient’s stage: stage II patients reported improved gait quality, ability to step on the heel and walk the stairs, raise from the floor with more confidence, and endure bigger loads during the day.  Within first two weeks of post-transplant period, noted was the increase of specific blood enzyme activity that by the end of 4-5th week was markedly decreased or even normalized. Usually, this effect was maintained for 2-5 months. Observed were also decreased pseudohypertrophy and strain of forearms and calves, contractures of knee and ankle joints, myocardiopathy manifestations, and respiratory insufficiency, especially in stage IVa-IVb patients.  DMD patients require continuous treatment (at least, once every 6-8 months) aimed at aversion of muscular atrophy progression.  Termination of the treatment results in further progression of the disease and limitation of physical activity.  Transplantation of embryonic stem cells terminates DMD progression, notwithstanding the stage of the process, and results in marked improvements.  Reported was restoration of cell immunity indices and decrease of cytotoxic activity of mesenchymal cells.


Novedades
2008-10-01
Prof. Aleksandr Smikodub tomó parte en el Congreso Europeo dedicado a los problemas de envejecimiento y medicina estética que tuvo lugar en Dusseldorf, Alemania

Prof. Aleksandr Smikodub tomó parte en el Congreso Europeo dedicado a los problemas de envejecimiento y medicina estética que tuvo lugar ...
  otros noticias
 
Articulos

25. Suspensiones que contienen c¨¦lulas troncales embrionales en el tratamiento de los tumores considerables antes de comenzar la terapia b¨¢sica.

Autor: Alex¨¢nder Smikodub   Cl¨ªnica de Terapia Celular de la Universidad M¨¦dica Nacional y del Centro de Tejidos Embrionales ¡°EmCell¡±   A los pacientes con tumores considerables y con complicaciones ...
  otros articulos
 
Patentes

Medicamento a base de suspensiones de las células fetales con efecto inmunosustituyente para el tratamiento del síndrome de inmunodeficiencia obtenida ...
   
 
Copyright © 1999-2009 EmCell.com